Selected Topics: Toxicology
Succinylcholine-induced Hyperkalemia in a Patient with Multiple Sclerosis

https://doi.org/10.1016/j.jemermed.2011.06.062Get rights and content

Abstract

Background

Succinylcholine administration is associated with hyperkalemia in patients with a variety of medical conditions, including many neuromuscular disorders. Nonetheless, there is a paucity of literature describing hyperkalemia after the administration of succinylcholine to patients with multiple sclerosis.

Case Report

This case report describes a 38-year-old woman with multiple sclerosis who developed life-threatening hyperkalemia after the administration of succinylcholine during rapid sequence intubation.

Conclusion

This case highlights the potential for iatrogenic hyperkalemia after succinylcholine in patients with neurologic diseases, including multiple sclerosis.

Introduction

Patients frequently present to the emergency department (ED) in need of prompt airway management. Expertise in this procedure, along with an intricate knowledge of the pharmacologic agents utilized to perform a rapid sequence intubation (RSI), is one of the defining features of the emergency physician (1). Succinylcholine, a depolarizing neuromuscular blocking agent, has long been the preferred paralytic for use in RSI 2, 3. Most of the contraindications to succinylcholine utilization relate to the potential to induce hyperkalemia, which can occur as a result of receptor upregulation in advanced neuromuscular disorders, including spinal cord injury and muscular dystrophy 3, 4, 5, 6, 7. Multiple sclerosis is a debilitating, immune-mediated disease characterized by demyelination, axonal damage, and ultimately, scar formation in the central nervous system 8, 9. Although hyperkalemia after the administration of succinylcholine to a patient with multiple sclerosis is frequently discussed, documented cases in the literature are rare 3, 9, 10.

Section snippets

Case Report

A 38-year-old right-hand-dominant woman presented to the ED for increasing lower extremity weakness and shortness of breath. Two years before this admission, the patient developed lower extremity weakness, and was diagnosed with multiple sclerosis. She was treated with steroids, with resolution of symptoms. Several months later, she developed left-sided weakness and again was treated with steroids, although after this second exacerbation, she developed some residual weakness involving the left

Discussion

Succinylcholine, or diacetylcholine (Figure 2), is the only depolarizing neuromuscular blocker currently approved for use in the United States. By binding to the two alpha subunits on the nicotinic receptor, a conformational change ensues and the channel opens, thereby permitting the influx of calcium and sodium, and the efflux of potassium 3, 11, 12. Because succinylcholine is not degraded by acetylcholinesterase, it remains bound to the receptor longer than acetylcholine itself would,

Conclusion

Succinylcholine-induced hyperkalemia is well described with various neuromuscular disorders. Although not widely reported with multiple sclerosis, a case of a 38-year-old woman with life-threatening hyperkalemia after the administration of a depolarizing neuromuscular blocking agent is presented.

References (16)

There are more references available in the full text version of this article.

Cited by (0)

View full text